CD40 Ligand

"CD40 Ligand" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A membrane glycoprotein and differentiation antigen expressed on the surface of T-cells that binds to CD40 ANTIGENS on B-LYMPHOCYTES and induces their proliferation. Mutation of the gene for CD40 ligand is a cause of HYPER-IGM IMMUNODEFICIENCY SYNDROME, TYPE 1.

Descriptor ID	D023201
MeSH Number(s)	D12.644.276.374.750.124 D12.776.395.550.185 D12.776.467.374.750.124 D12.776.543.550.198 D23.529.374.750.124
Concept/Terms	CD40 Ligand CD40 Ligand gp39 Antigen, T-Cell T-Cell gp39 Antigen gp39 Antigen, T Cell CD40L Tumor Necrosis Factor Ligand Superfamily Member 5 Antigen, CD154 CD154 Antigen T-B Cell Activating Molecule TNF Superfamily, Member 5 CD154 Antigens Antigens, CD154

Below are MeSH descriptors whose meaning is more general than "CD40 Ligand".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Peptides [D12.644]
Intercellular Signaling Peptides and Proteins [D12.644.276]
Cytokines [D12.644.276.374]
Tumor Necrosis Factors [D12.644.276.374.750]
CD40 Ligand [D12.644.276.374.750.124]
Proteins [D12.776]
Glycoproteins [D12.776.395]
Membrane Glycoproteins [D12.776.395.550]
CD40 Ligand [D12.776.395.550.185]
Intercellular Signaling Peptides and Proteins [D12.776.467]
Cytokines [D12.776.467.374]
Tumor Necrosis Factors [D12.776.467.374.750]
CD40 Ligand [D12.776.467.374.750.124]
Membrane Proteins [D12.776.543]
Membrane Glycoproteins [D12.776.543.550]
CD40 Ligand [D12.776.543.550.198]
Biological Factors [D23]
Intercellular Signaling Peptides and Proteins [D23.529]
Cytokines [D23.529.374]
Tumor Necrosis Factors [D23.529.374.750]
CD40 Ligand [D23.529.374.750.124]

Below are MeSH descriptors whose meaning is related to "CD40 Ligand".

Below are MeSH descriptors whose meaning is more specific than "CD40 Ligand".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "CD40 Ligand" by people in this website by year, and whether "CD40 Ligand" was a major or minor topic of these publications.

Bar chart showing 18 publications over 16 distinct years, with a maximum of 2 publications in 2011 and 2021

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1999	0	1	1
2000	0	1	1
2001	1	0	1
2002	1	0	1
2003	1	0	1
2004	0	1	1
2006	0	1	1
2007	0	1	1
2008	0	1	1
2010	1	0	1
2011	1	1	2
2014	1	0	1
2020	0	1	1
2021	1	1	2
2022	0	1	1
2023	1	0	1

Below are the most recent publications written about "CD40 Ligand" by people in Profiles.

Hazra B, Das Sarma J. The CD40/CD40 ligand dyad and its downstream effector molecule ISG54 in relating acute neuroinflammation with persistent, progressive demyelination. IUBMB Life. 2024 06; 76(6):313-331.

View in: PubMed
Ma C, Fu Q, Diggs LP, McVey JC, McCallen J, Wabitsch S, Ruf B, Brown Z, Heinrich B, Zhang Q, Rosato U, Wang S, Cui L, Berzofsky JA, Kleiner DE, Bosco DB, Wu LJ, Lai CW, Rotman Y, Xie C, Korangy F, Greten TF. Platelets control liver tumor growth through P2Y12-dependent CD40L release in NAFLD. Cancer Cell. 2022 09 12; 40(9):986-998.e5.

View in: PubMed
Saadi F, Chakravarty D, Kumar S, Kamble M, Saha B, Shindler KS, Das Sarma J. CD40L protects against mouse hepatitis virus-induced neuroinflammatory demyelination. PLoS Pathog. 2021 12; 17(12):e1010059.

View in: PubMed
Fadul CE, Mao-Draayer Y, Ryan KA, Noelle RJ, Wishart HA, Channon JY, Kasper IR, Oliver B, Mielcarz DW, Kasper LH. Safety and Immune Effects of Blocking CD40 Ligand in Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2021 11; 8(6).

View in: PubMed
Pollack KE, Meneveau MO, Melssen MM, Lynch KT, Koeppel AF, Young SJ, Turner S, Kumar P, Sol-Church K, Mauldin IS, Slingluff CL. Incomplete Freund's adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment. J Immunother Cancer. 2020 04; 8(1).

View in: PubMed
Amirkhosravi A, Boulaftali Y, Robles-Carrillo L, Meyer T, McKenzie SE, Francis JL, Bergmeier W. CalDAG-GEFI deficiency protects mice from Fc?RIIa-mediated thrombotic thrombocytopenia induced by CD40L and ?2GPI immune complexes. J Thromb Haemost. 2014 Dec; 12(12):2113-9.

View in: PubMed
M?ller M, Blum HE, Er F, Thimme R, Semmo N. [Cellular immune response in Hepatitis C infection: role of CD154 expression and clinical relevance]. Dtsch Med Wochenschr. 2011 May; 136(20):1073-7.

View in: PubMed
Witkowski M, Spangenberg HC, Neumann-Haefelin C, B?ttner N, Breous E, Kersting N, Drognitz O, Hopt UT, Blum HE, Semmo N, Thimme R. Lack of ex vivo peripheral and intrahepatic a-fetoprotein-specific CD4+ responses in hepatocellular carcinoma. Int J Cancer. 2011 Nov 01; 129(9):2171-82.

View in: PubMed
Mueller M, Spangenberg HC, Kersting N, Altay T, Blum HE, Klenerman P, Thimme R, Semmo N. Virus-specific CD4+ T cell responses in chronic HCV infection in blood and liver identified by antigen-specific upregulation of CD154. J Hepatol. 2010 Jun; 52(6):800-11.

View in: PubMed
Alugupalli KR. A distinct role for B1b lymphocytes in T cell-independent immunity. Curr Top Microbiol Immunol. 2008; 319:105-30.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement